Skip to main content

Advertisement

Table 3 Heart function, plasma and myocardial adiponectin levels in control, diabetic, and diabetic treated with low and high doses of exenatide

From: Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats

  C D DTL DTH
Number 7 10 10 9
LVSP (mmHg) 142.48 ± 11.01 78.77 ± 14.56* 90.25 ± 10.67*,# 102.42 ± 9.32*,#,$
LVEDP (mmHg) 6.5 ± 1.42 11.2 ± 1.68* 9.58 ± 3.18*,# 7.28 ± 2.61#,$
+dp/dtmax (mmHg.s−1) 7780.51 ± 809.47 2182.12 ± 344.15* 3735.14 ± 384.41*,# 3892.61 ± 535.43*,#
-dp/dtmax (mmHg.s−1) 7014.15 ± 746.47 1838.39 ± 206.33* 3774.86 ± 419.87*,# 3997.33 ± 782.37*,#
Plasma adiponectin (ng/ml) 1877.96 ± 377.97 1032.33 ± 170.23* 1387.72 ± 343.71# 1396.82 ± 185.52#
Myocardial adiponectin (ng/μg protein) 0.13 ± 0.04 0.11 ± 0.03 0.13 ± 0.06 0.16 ± 0.05
  1. Values were obtained at sacrifice, after administration with or without 8 weeks of exenatide treatment. Control (C), diabetic (D), diabetic treated with low dose (2 μg · kg−1.d−1) of exenatide (DTL), diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide (DTH). LVSP: left ventricular systolic pressure; LVEDP: left ventricular end diastolic pressure; −dp/dtmax: the maximum descent-speed of pressure in isovolumic relaxation period in the left ventricle; +dp/dtmax: the maximum ascendent-speed of pressure in isovolumic contraction period in the left ventricle. All values were expressed as mean ± S.E.M. *P < 0.05 or 0.01 vs. C; #P < 0.05 vs. D; $P < 0.05 vs. DTL.